000			02251cam a2200229 4500500
005			20250112030511.0
041			_afre
042			_adc
100	1	0	_aJroundi, Chaymae _eauthor
700	1	0	_a Baybay, Hanane _eauthor
700	1	0	_a Kassel, Jihad _eauthor
700	1	0	_a Douhi, Zakia _eauthor
700	1	0	_a Soughi, Meryem _eauthor
700	1	0	_a Elloudi, Sara _eauthor
700	1	0	_a Mernissi, Fatima Zahra _eauthor
245	0	0	_aNd-YAG laser and recalcitrant warts: A 28-case series
260			_c2023.
500			_a66
520			_aWarts are benign epithelial growths caused by the Human Papilloma Virus (HPV). Some lesions may be more difficult to treat, due to their location or size. The objective of our study was to evaluate the efficacy and safety of Nd-YAG laser in the management of recalcitrant warts. Materials and methods: A prospective study was conducted in the dermatology department of the Hassan II University Hospital in Fes. Over a 4-year period, from 2017 to 2021, 28 patients with recalcitrant warts were treated using Nd-YAG laser. The parameters used were a spot size of 3 to 5 mm, a pulse duration at 20 ms, and fluence of between 150 and 240 J/cm2 with local anesthesia. The endpoint was obtained in all our patients with immediate post-laser dermoscopic control to minimize the number of sessions required. Results: The average age of our patients was 31 years. The locations treated included the face, palms, and soles of the feet, as well as periungual warts. The number of sessions was between 1 and 3, with myrmecia warts and lesions larger than 1 cm requiring additional sessions. The side effects observed were hemorrhagic bullae after the session, which were resolved with local wound care. One case of nail dystrophy was noted in a child. The complete remission rate was 92.85% (26/28). During a median follow-up period of 25 months, 3 recurrences were observed. Conclusion: We propose the Nd-YAG laser as a safe and effective means for the removal or reduction of resistant and profuse warts.
786	0		_nCahiers Santé Médecine Thérapeutique | 32 | 3 | 2023-05-01 | p. 117-121 | 2780-8858
856	4	1	_uhttps://shs.cairn.info/journal-cahiers-sante-medecine-therapeutique-2023-3-page-117?lang=en
999			_c152417 _d152417